AMLN Insider Trading Activity and SEC Form 4 Filings
AMLN insider trading summary
No open-market insider purchases or sales of Amylin Pharmaceuticals Inc (AMLN) have been reported on SEC Form 4 in the past 12 months.
Latest AMLN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 29, 2012 | Lloyd A Rowland | VP, Chief Compliance Officer | Sell | $75K (3,000 @ $25.00) |
| Mar 28, 2012 | Lloyd A Rowland | VP, Chief Compliance Officer | Sell | $114K (5,000 @ $22.83) |
| Mar 1, 2012 | Vincent P Mihalik | SVP, Chief Commercial Officer | Sell | $21K (1,231 @ $17.11) |
| Mar 1, 2012 | Mark J Gergen | SVP, Corporate Development | Sell | $32K (1,846 @ $17.11) |
| Mar 1, 2012 | Orville G Kolterman | SVP, Chief Medical Officer | Sell | $32K (1,846 @ $17.11) |
| Mar 1, 2012 | Christian Weyer | SVP, Research & Development | Sell | $21K (1,231 @ $17.11) |
| Mar 1, 2012 | Mark G Foletta | SVP, Chief Financial Officer | Sell | $32K (1,846 @ $17.11) |
| Mar 1, 2012 | Daniel Bradbury | President & Chief Executive Of | Sell | $26K (1,539 @ $17.11) |
| Mar 1, 2012 | Harry J Leonhardt | SVP, Legal, Compliance and Cor | Sell | $21K (1,231 @ $17.11) |
| Mar 1, 2012 | Marcea Bland Lloyd | SVP, Chief Administrative Offi | Sell | $32K (1,846 @ $17.11) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.